[1] |
ESCOBAR-MORREALE H F. Polycystic ovary syndrome:definition,aetiology,diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5):270-284. doi:10.1038/nrendo.2018.24.
|
[2] |
YU O, CHRIST J P, SCHULZE-RATH R, et al. Incidence,prevalence,and trends in polycystic ovary syndrome diagnosis:a United States population-based study from 2006 to 2019[J]. Am J Obstet Gynecol, 2023, 229(1):39.e1-39.e12. doi:10.1016/j.ajog.2023.04.010.
|
[3] |
GABE M, SKOV-JEPPESEN K, GASBJERG L S, et al. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment[J]. Pharmacol Res, 2022,176:106058. doi:10.1016/j.phrs.2022.106058.
|
[4] |
VASTO S, AMATO A, PROIA P, et al. Is the secret in the gut? SuperJump activity improves bone remodeling and glucose homeostasis by GLP-1 and GIP peptides in eumenorrheic women[J]. Biology (Basel), 2022, 11(2):296. doi:10.3390/biology11020296.
|
[5] |
ZHANG Z Q, HÖLSCHER C. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models[J]. Peptides, 2020,125:170184. doi:10.1016/j.peptides.2019.170184.
|
[6] |
AHRÉN B. Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion:the human literature revisited and a systematic study in model experiments in mice[J]. J Diabetes Investig, 2022, 13(10):1655-1665. doi:10.1111/jdi.13836.
|
[7] |
HÖLSCHER C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models[J]. Neuropharmacology, 2018, 136(Pt B):251-259. doi:10.1016/j.neuropharm.2018.01.040.
|
[8] |
REGAZZO D, BERTAZZA L, GALLETTA E, et al. The GIP/GIPR axis in medullary thyroid cancer:clinical and molecular findings[J]. Endocr Relat Cancer, 2022, 29(5):273-284. doi:10.1530/ERC-21-0258.
|
[9] |
ROMITTI M, FABRIS V C, ZIEGELMANN P K, et al. Association between PCOS and autoimmune thyroid disease:a systematic review and meta-analysis[J]. Endocr Connect, 2018, 7(11):1158-1167. doi:10.1530/EC-18-0309.
|
[10] |
SHEKHAWAT V S, BHANSALI S, DUTTA P, et al. Glucose-dependent insulinotropic polypeptide(GIP)resistance and β-cell dysfunction contribute to hyperglycaemia in acromegaly[J]. Sci Rep, 2019, 9(1):5646. doi:10.1038/s41598-019-41887-7.
|
[11] |
HEIMBÜRGER S M, BERGMANN N C, AUGUSTIN R, et al. Glucose-dependent insulinotropic polypeptide(GIP)and cardiovascular disease[J]. Peptides, 2020, 125:170-174. doi:10.1016/j.peptides.2019.170174.
|
[12] |
KHAN D, OJO O O, WOODWARD O R, et al. Evidence for involvement of GIP and GLP-1 receptors and the gut-gonadal axis in regulating female reproductive function in mice[J]. Biomolecules, 2022, 12(12):1736. doi:10.3390/biom12121736.
|
[13] |
NISHIYAMA Y, HASEGAWA T, FUJITA S, et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells[J]. J Steroid Biochem Mol Biol, 2018, 178:82-88. doi:10.1016/j.jsbmb.2017.11.004.
|
[14] |
DHANKHAR S, CHAUHAN S, MEHTA D K, et al. Novel targets for potential therapeutic use in diabetes mellitus[J]. Diabetol Metab Syndr, 2023, 15(1):17. doi:10.1186/s13098-023-00983-5.
|
[15] |
STEPTO N K, CASSAR S, JOHAM A E, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp[J]. Hum Reprod, 2013, 28(3):777-784. doi:10.1093/humrep/des463.
|
[16] |
CENA H, CHIOVATO L, NAPPI R E. Obesity,polycystic ovary syndrome,and infertility:a new avenue for GLP-1 receptor agonists[J]. J Clin Endocrinol Metab, 2020, 105(8):e2695-2709. doi:10.1210/clinem/dgaa285.
|
[17] |
THANNICKAL A, BRUTOCAO C, ALSAWAS M, et al. Eating,sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS):a systematic review and meta-analysis[J]. Clin Endocrinol(Oxf), 2020, 92(4):338-349. doi:10.1111/cen.14153.
|
[18] |
WILLIAMS S, FIDO D, SHEFFIELD D. Polycystic ovary syndrome(PCOS)and non-suicidal self-injury(NSSI):a community-based study[J]. Healthcare (Basel), 2022, 10(6):1118. doi:10.3390/healthcare10061118.
|
[19] |
袁莹莹, 赵君利. 多囊卵巢综合征流行病学特点[J]. 中国实用妇科与产科志, 2019, 35(3):261-264.
|
|
YUAN Y Y, ZHAO J L. Epidemiological features of polycystic ovary syndrome[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(3):261-264. doi:10.19538/j.fk2019030102.
|
[20] |
马良坤. 多囊卵巢综合征的胰岛素增敏治疗[D]. 北京: 中国协和医科大学, 2008.
|
|
MA L K. Insulin sensitizing treatment of polycystic ovarian syndrome[D]. Beijing: Peking Union Medical College, 2008.
|
[21] |
McCLEAN P L, IRWIN N, CASSIDY R S, et al. GIP receptor antagonism reverses obesity,insulin resistance,and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet[J]. Am J Physiol Endocrinol Metab, 2007, 293(6):E1746-E1755. doi:10.1152/ajpendo.00460.2007.
|
[22] |
CLEMENTS R H, GONZALEZ Q H, LONG C I, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus[J]. Am Surg. 2004, 70(1):1-5.
|
[23] |
张宏伟. 腹腔镜胃旁路手术对肥胖型Ⅱ型糖尿病的临床研究[D]. 长春: 吉林大学, 2019.
|
|
ZHANG H W. Clinical research of laparoscopic gastric bypass operation in promoting the type 2 diabetes mellitus[D]. Changchun: Jilin University, 2019.
|
[24] |
LYU X, YAN K, HU W, et al. Safflower yellow and its main component hydroxysafflor yellow A alleviate hyperleptinemia in diet-induced obesity mice through a dual inhibition of the GIP-GIPR signaling axis[J]. Phytother Res,2023 March 21. doi:10.1002/ptr.7788. [Epub ahead of print].
|
[25] |
徐丹凤, 谢华, 陈敏, 等. 亚麻籽油对肥胖2型糖尿病小鼠体质量、血糖、胃肠激素水平的影响[J]. 山东医药, 2019, 59(32):5-7.
|
|
XU D F, XIE H, CHEN M, et al. Effects of linseed oil on body weight,blood glucose and gastrointestinal hormone secretion in obese type 2 diabetic mice[J]. Shandong Medical Journal, 2019, 59(32):5-7.
|
[26] |
SVENDSEN P F, NILAS L, MADSBAD S, et al. Incretin hormone secretion in women with polycystic ovary syndrome:roles of obesity,insulin sensitivity,and treatment with metformin[J]. Metabolism, 2009, 58(5):586-593. doi:10.1016/j.metabol.2008.11.009.
|
[27] |
李萍, 沙艳伟, 丁露, 等. PCOS患者肠促胰素水平变化及其在发病中的作用研究[J]. 中国妇幼保健, 2015, 30(31):5421-5423.
|
|
LI P, SHA Y W, DING L, et al. Changes of incretin levels in PCOS patients and its role in pathogenesis of PCOS[J]. Maternal and Child Health Care of China, 2015, 30(31):5421-5423.
|
[28] |
张红裔, 吕洪亮, 谷洋, 等. 非肥胖型2型糖尿病空肠回肠侧侧吻合术后血糖与GIP变化的相关性研究[J]. 中国实验诊断学, 2023, 27(7):821-824.
|
|
ZHANG H Y, LYU H L, GU Y, et al. Correlation between blood glucose and GIP changes after lateral jejuno-ileal anastomosis in non-obese type 2 diabetes mellitus[J]. Chinese Journal of Laboratory Diagnosis, 2023, 27(7):821-824.
|
[29] |
THOMAS M K, NIKOOIENEJAD A, BRAY R, et al. Dual GIP and GLP-1 receptor agonist Tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes[J]. J Clin Endocrinol Metab, 2021, 106(2):388-396. doi:10.1210/clinem/dgaa863.
|
[30] |
DIAMANTI-KANDARAKIS E, DUNAIF A. Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6):981-1030. doi:10.1210/er.2011-1034.
|
[31] |
徐晶, 申丽媛, 屈清华. 基于PI3K/AKT通路探究柚皮素改善多囊卵巢综合征大鼠胰岛素抵抗的作用机制[J]. 天津医药, 2022, 50(3):270-275.
|
|
XU J, SHEN L Y, QU Q H. Study on the mechanism of naringenin improving insulin resistance in rats with polycystic ovary syndrome based on PI3K/AKT pathway[J]. Tianjin Med J, 2022, 50(3):270-275. doi:10.11958/20212367.
|
[32] |
KIM S J, NIAN C, KARUNAKARAN S, et al. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis,and improved glucose homeostasis[J]. PLoS One, 2012, 7(7):e40156. doi:10.1371/journal.pone.0040156.
|
[33] |
SVENDSEN P F, JENSEN F K, HOLST J J, et al. The effect of a very low calorie diet on insulin sensitivity,beta cell function,insulin clearance,incretin hormone secretion,androgen levels and body composition in obese young women[J]. Scand J Clin Lab Invest, 2012, 72(5):410-419. doi:10.3109/00365513.2012.691542.
|
[34] |
MILEWICZ T, MIGACZ K, KIAłKA M, et al. Basic and meal stimulated plasma GIP levels are higher in lean PCOS women with FAI over 5[J]. Exp Clin Endocrinol Diabetes, 2016, 124(2):77-81. doi:10.1055/s-0042-101165.
|
[35] |
WOODWARD O R M, GRIBBLE F M, REIMANN F, et al. Gut peptide regulation of food intake-evidence for the modulation of hedonic feeding[J]. J Physiol, 2022, 600(5):1053-1078. doi:10.1113/JP280581.
|
[36] |
ADRIAENSSENS A E, BIGGS E K, DARWISH T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake[J]. Cell Metab, 2019, 30(5):987-996.e6. doi:10.1016/j.cmet.2019.07.013.
|
[37] |
FU Y, KANEKO K, LIN H Y, et al. Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus[J]. Endocrinology, 2020, 161(9):bqaa102. doi:10.1210/endocr/bqaa102.
|
[38] |
LISKIEWICZ A, KHALIL A, LISKIEWICZ D, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice[J]. Nat Metab, 2023, 5(12):2075-2085. doi:10.1038/s42255-023-00931-7.
|
[39] |
CANTACORPS L, COULL B M, FALCK J, et al. Gut-derived peptide hormone receptor expression in the developing mouse hypothalamus[J]. PLoS One, 2023, 18(8):e0290043. doi:10.1371/journal.pone.0290043
|
[40] |
MOFFETT R C, NAUGHTON V. Emerging role of GIP and related gut hormones in fertility and PCOS[J]. Peptides, 2020,125:170233. doi:10.1016/j.peptides.2019.170233.
|